Catalent, Inc.

$ 63.48 0.00 %

Catalent, Inc., operating globally through its various subsidiaries, specializes in the development and production of comprehensive solutions for a wide array of products, including pharmaceutical drugs, protein-based biologics, advanced cell and gene therapies, and consumer health items. The company's operations are strategically divided into four key segments: Biologics; Softgel and Oral Technologies; Oral and Specialty Delivery; and Clinical Supply Services. The Softgel and Oral Technologies division focuses on the formulation, development, and manufacturing of soft capsules. These are utilized in a diverse range of client products, such as prescription medications, over-the-counter drugs, nutritional supplements, unit-dose cosmetics, and medicinal preparations for animal health. Within the Biologics segment, Catalent undertakes the creation of biologic cell lines, develops and manufactures both cell therapy and viral-based gene therapy, and handles the formulation and production of parenteral dose forms, including vials, prefilled syringes, and cartridges. This segment also provides essential analytical development and testing capabilities. The Oral and Specialty Delivery segment offers extensive formulation, development, and manufacturing expertise across various technologies. It provides integrated downstream solutions spanning clinical development and commercial supply. This segment also features a dedicated oral delivery solutions platform, encompassing preclinical screening, formulation, analytical development, and current good manufacturing practices (cGMP) services. Finally, the Clinical Supply Services segment delivers vital support for drug and biologic clinical trials. Its services include manufacturing, specialized packaging, secure storage, efficient distribution, and comprehensive inventory management. This segment also offers "FastChain," a demand-led clinical supply service. Catalent serves a broad client base, including pharmaceutical, biotechnology, and consumer health organizations, alongside companies in other healthcare sectors like animal health and medical devices, and even the cosmetics industry. The company was founded in 2007 and maintains its headquarters in Somerset, New Jersey.

CEO: Alessandro Maselli - https://www.catalent.com

Price objectif

$74.25 16.97 %

Recommandation

Hold

DCF

$ 0.00

Loading data...

CTLT vs S&P500

Loading data...

No data available.

Quick ratio

1.96

suggests a healthy liquidity position, showing that the company can likely meet its short-term obligations.

P/E ratio

-27.84

may indicate that the company is undervalued or has poor growth prospects.

EPS

-2.28

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

-25.32 %

indicates low profitability, suggesting that the company is not using equity efficiently to generate profits.

ROIC

-8.53 %

does not generate enough return to cover its financing costs, which indicates value destruction and may pose long-term profitability issues.

WACC

-

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

1.36

means it relies more on debt, which can increase financial risk.

Free cash flow per share

-0.33

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

0.00 %

the dividend payout ratio is the measure of dividends paid out to shareholders relative to the company's net income.

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
4 indicates moderate financial health
Altman score
1.60 indicates a high risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
0.28 indicates liquidity risk, as the company may not have enough cash to meet its immediate obligations
Debt Ratio
0.50 indicates a moderate level of debt, which is generally acceptable but may present some risk
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.